Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Novel MST1 inhibitor accelerates murine liver regeneration following partial hepatectomy with improved survival in models of steatohepatitis

ABSTRACT: Novel MST1 inhibitor accelerates murine liver regeneration following partial hepatectomy with improved survival in models of steatohepatitis

PROVIDER: PRJNA964752 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24377464_1.fastq.gz	Fastqsanger.gz
	SRR24377464_2.fastq.gz	Fastqsanger.gz
	SRR24377465_1.fastq.gz	Fastqsanger.gz
	SRR24377465_2.fastq.gz	Fastqsanger.gz
	SRR24377466_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Novel MST1 inhibitor accelerates murine liver regeneration following partial hepatectomy with improved survival in models of steatohepatitis

Project description:Disrupted hepatocyte regeneration following surgical resection remains a clinical problem with few therapeutic options. The current treatment paradigm relies on supportive therapy until homeostasis can be achieved. Pharmacologic acceleration of regeneration may provide an alternative therapeutic avenue. Therefore, we aimed to generate a small molecule inhibitor that could accelerate liver regeneration in both normal and diseased murine preclinical models. mCLC846 demonstrated on target inhibition of MST1 and reduced EGFR inhibition which resulted in Yes-associated protein (YAP) activation. Oral delivery of mCLC846 perioperatively resulted in accelerated liver regeneration and improved survival in diet induced NASH models. Transcriptional analysis suggested that mCLC846 enhanced the normal regenerative pathways induced following liver resection. Overall, pharmacological acceleration of liver regeneration with mCLC846 was feasible, had an acceptable therapeutic index, and provided survival benefit in models of diet induced non-alcoholic steatohepatitis.

2023-11-01 | GSE231391 | GEO

Partial hepatectomy accelerates colorectal metastasis by priming a prometastatic niche in the liver

Project description:Partial hepatectomy accelerates colorectal metastasis by priming a prometastatic niche in the liver

| PRJNA1064897 | ENA

Partial hepatectomy accelerates colorectal metastasis by priming a prometastatic niche in the liver

Project description:Despite being the standard of care for patients with Stage IV colorectal cancer (CRC), the effects of a resection of liver metastasis on the metastatic disease are poorly understood. To elucidate the influence of surgical metastasectomies on metastasized CRC, we investigated the cellular and molecular effects of partial hepatectomy in a mouse model of orthograde CRC liver metastasis.

2024-06-02 | GSE253251 | GEO

Comparison of hepatic gene change after partial hepatectomy

Project description:Partial hepatectomy, resection of a portion of liver mass, indues significant liver regenerative responses that consist of numerous genetic changes. To identify specific genetic changes, we compare the liver of mice underwent either hepatectomy or sham operation.

2010-11-01 | GSE22879 | GEO

DNA dioxygenase Tet2 regulates liver regeneration after partial hepatectomy [dateset2]

Project description:To investigate how liver macrophages regulate liver regeneration after partial hepatectomy, we isolate the macrophages 0, 24, and 48h after partial hepatectomy(PHx). We performed gene expression profiling analysis using data obtained from RNA-seq of liver macrophages 0,24,48h after partial hepatectomy.

2025-05-21 | GSE233515 | GEO

Comparison of hepatic gene change after partial hepatectomy

2010-11-01 | E-GEOD-22879 | biostudies-arrayexpress

A small molecule MST1/2 inhibitor accelerates murine liver regeneration with improved survival in models of steatohepatitis.

Project description:Dysfunctional liver regeneration following surgical resection remains a major cause of postoperative mortality and has no therapeutic options. Without targeted therapies, the current treatment paradigm relies on supportive therapy until homeostasis can be achieved. Pharmacologic acceleration of regeneration represents an alternative therapeutic avenue. Therefore, we aimed to generate a small molecule inhibitor that could accelerate liver regeneration with an emphasis on diseased models, which represent a significant portion of patients who require surgical resection and are often not studied. Utilizing a clinically approved small molecule inhibitor as a parent compound, standard medicinal chemistry approaches were utilized to generate a small molecule inhibitor targeting serine/threonine kinase 4/3 (MST1/2) with reduced off-target effects. This compound, mCLC846, was then applied to preclinical models of murine partial hepatectomy, which included models of diet-induced metabolic dysfunction-associated steatohepatitis (MASH). mCLC846 demonstrated on target inhibition of MST1/2 and reduced epidermal growth factor receptor inhibition. The inhibitory effects resulted in restored pancreatic beta-cell function and survival under diabetogenic conditions. Liver-specific cell-line exposure resulted in Yes-associated protein activation. Oral delivery of mCLC846 perioperatively resulted in accelerated murine liver regeneration and improved survival in diet-induced MASH models. Bulk transcriptional analysis of regenerating liver remnants suggested that mCLC846 enhanced the normal regenerative pathways and induced them following liver resection. Overall, pharmacological acceleration of liver regeneration with mCLC846 was feasible, had an acceptable therapeutic index, and provided a survival benefit in models of diet-induced MASH.

| S-EPMC10962727 | biostudies-literature

Partial hepatectomy 1, 2, 4, 6h

Project description:Partial hepatectomy 1, 2, 4, 6h

| PRJNA100387 | ENA

SILAC-Based Characterization of Plasma-Derived Extracellular Vesicles in Patients Undergoing Partial Hepatectomy

Project description:Post-hepatectomy liver failure (PHLF) remains a significant risk for patients undergoing partial hepatectomy (PHx). Reliable prognostic markers and treatments to enhance liver regeneration are lacking. Plasma nanoparticles, including lipoproteins, exosomes, and extracellular vesicles (EVs), can reflect systemic and tissue-wide proteostasis and stress, potentially aiding liver regeneration. Our study included nine patients with hepatocellular carcinoma (HCC) undergoing PHx. Patient plasma was collected before PHx as well as 1 and 5 days after and the EV-protein repertoire was analysed by quantitative mass spectrometry using a super-SILAC mix prepared from primary and cancer cell lines. This longitudinal proteomic analysis of the EVs circulating in the plasma of human patients undergoing PHx uncovers proteomic signatures associated with PHLF, which reflect dying hepatocytes and endothelial cells and were already present before PHx.

2025-08-11 | PXD059885 | Pride

Partial hepatectomy 1, 2, 4, 6h

Project description:Adult male Sprague-Dawley rats (275-350 g) were anesthetized and subjected to two-thirds PHx. Liver sections removed by partial hepatectomy (PHx) were collected and used both as controls (time=0) and as individual reference material for each animal to reduce the error introduced by animal-to-animal variability. At 1, 2, 4, and 6 hours following PHx, rats were killed and liver samples were harvested. Keywords: Time series PHx (1, 2, 4, 6h)

2007-04-06 | GSE7415 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data